Lazurite Adds Intuitive Modern Medical Solutions as New Distributor of the ArthroFree System

Medical device and technology company Lazurite® today announced that it has added Intuitive Modern Medical Solutions (IMMS) as a distributor of its ArthroFree® Wireless Camera System for the state of New York except New York City.

ArthroFree

ArthroFree is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus. Without camera-cable-related interruptions and contamination concerns, surgeons can keep their eyes on the monitor—and on their patients’ well-being.

Lazurite President Leah Brownlee

Lazurite is delighted to have IMMS join our growing distributor network and in-house sales team. They are a great fit for us with their focus on innovative new technology and coverage of New York state. As we do at Lazurite, IMMS strongly emphasizes the education and training of its team members so that they may be an asset to customers before, during, and after surgery.”

Founded by Principal and CEO Jeffrey Thomas in 2016, IMMS is based in Victor, N.Y., southeast of Rochester. The company currently has nine representatives and an offering encompassing arthroscopy and laparoscopy, extremity, as well as sports tissue and biologics, and total joint replacement. As an added benefit for surgeons and its manufacturer partners, IMMS has an evaluation laboratory in its office.

Principal and CEO IMMS Jeffrey Thomas

“Our manufacturer partnerships are mostly focused on emerging technologies that fit unmet needs in hospitals and surgery centers and have the potential to reduce overhead expenses, all of which makes Lazurite a great fit for us.”

He added, “They are currently partnered in a study of ArthroFree with the University of Buffalo, which has a strong reputation here in western New York, and they’ve already initiated sales opportunities here with clinical evaluations and demos. The news about the availability of this novel technology in our region is spreading. We have demoed ArthroFree in our onsite lab several times already with positive feedback.”

Thomas has more than 25 years of operating room experience, beginning as a hospital corpsman in the United States Navy. He started his business career as a medical device sales associate and worked his way up to a full-line territory manager before moving into management and founding IMMS. Over that time, he has specialized in sports medicine, sports tissue and biologics, arthroscopy/laparoscopy, and total joint preservation.

SourceLazurite

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”